AnaptysBio is a speculative biotech with a perfect four-quarter earnings beat streak, strong peer-best margins and 57.2% upside to the analyst target, but it is heavily dependent on GSK and one pipeline asset and carries 40% short interest.
Thesis pillars
- Gsk Pipeline Concentration Risk↓Deteriorating
- Consistent Earnings Beat Streak↑Improving
- Revenue Growth Lumpy Milestones→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 3, 2026
AnaptysBio, Inc. (ANAB) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $47.51, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Concentration risk — Pipeline: rosnilimab.
AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned clinical-stage candidates: rosnilimab (Phase 2b completed for RA), ANB033 (Phase 1b for celiac disease and EoE), and ANB101 (Phase 1a). Revenue came from GSK milestones and... Read more
Hold if already holding. Not a fresh buy at $47.51, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Concentration risk — Pipeline: rosnilimab. Chart setup: RSI 47 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: speculative.
About AnaptysBio, Inc.
About AnaptysBio, Inc.
AnaptysBio's lead asset, rosnilimab, completed a 424-patient global Phase 2b trial for moderate-to-severe rheumatoid arthritis in 2025, meeting its primary DAS28-CRP endpoint across all three doses; ACR20 response at the 600 mg Q2W dose reached 75.2% versus 52.8% for placebo. The company had no product revenue in 2025, earning milestone and royalty income from GSK's Jemperli collaboration — GSK reported $1.1 billion in Jemperli sales for 2025, up more than 80% from $598 million in 2024.
AnaptysBio earns revenue from two financial collaborations: tiered royalties from GSK on Jemperli net sales (ranging from 8% below $1.0 billion to 25% above $2.5 billion under Amendment No. 3 to the GSK Agreement), with a $250.0 million royalty monetization agreement with Sagard Healthcare Royalty Partners limiting near-term cash receipts; and a license to Vanda Pharmaceuticals for imsidolimab (IL-36R antagonist), which provided a $10.0 million upfront payment plus $5.0 million for drug supply and up to $35.0 million in future milestones plus 10% royalties on net sales. In April 2026, the company completed the spin-off of First Tracks Biotherapeutics to hold those two financial collaborations. Two additional wholly owned programs are in early development: ANB033 (CD122 antagonist) is in Phase 1b cohorts for celiac disease and eosinophilic esophagitis, and ANB101 (BDCA2 modulator) entered a Phase 1 trial in healthy volunteers in March 2025.
Show full overview
The critical near-term milestone for AnaptysBio is the Phase 3 advancement decision for rosnilimab in rheumatoid arthritis, which the company stated it plans to update on in the first half of 2026. The 10-K discloses that while rosnilimab achieved positive Phase 2b results in RA, a prior Phase 2 trial in ulcerative colitis was not positive — demonstrating the indication-level binary risk for a multi-indication development program. The FDA accepted Vanda's BLA for imsidolimab in February 2026 with a target action date of December 12, 2026; approval would trigger the $5.0 million FDA milestone under the Vanda License Agreement, now accruing to First Tracks Biotherapeutics following the spin-off.
See also: Healthcare · Biotechnology
From AnaptysBio, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Oct 31, 2026Recent Developments — AnaptysBio, Inc.
Latest news
- NEWS AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside? - Yahoo Fin — Yahoo Finance Oct 31, 2026 neutral
- NEWS Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval? - Yahoo Finance — Yahoo Finance Oct 30, 2026 positive
- NEWS Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative? - Simply Wall St — Simply Wall St Oct 29, 2026 positive
- NEWS AnaptysBio (ANAB) Gains From Jemperli Approval, Is The Royalty Upside Already Priced In? - Simply Wall Street — Simply Wall Street Oct 27, 2026 positive
- NEWS AnaptysBio (ANAB) Gains From Jemperli Approval, Is The Royalty Upside Already Priced In? - Simply Wall St — Simply Wall St Oct 27, 2026 positive
Latest item Oct 31, 2026 · Generated 2026-11-05T11:34:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyGSK10-K Item 1A: 'Our existing collaboration with GSK and other collaborations are important to our business ... If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.'
- HIGHpipelinerosnilimab10-K Item 1A: 'We are assessing advancement to Phase 3 of clinical development of rosnilimab for RA, and have no history of commercializing biotechnology products'
Material Events(8-K, last 90d)
- 2026-05-11Item 5.02LOWChristopher M. Murphy appointed CFO of AnaptysBio effective May 11, 2026; previously CFO of Third Harmonic Bio (Jan 2024–Dec 2025). Clean handoff; no disagreement with company practices cited.SEC filing →
- 2026-04-20Item 1.01MEDIUMAnaptysBio entered Separation and Distribution Agreement and Transition Services Agreement on April 20, 2026 completing spin-off of First Tracks Biotherapeutics; TRAX shares distributed pro rata to ANAB shareholders; TRAX began trading on Nasdaq.SEC filing →
- 2026-03-27Item 1.01MEDIUMBoard approved spin-off of First Tracks Biotherapeutics on March 26, 2026; SpinCo entered private placement Purchase Agreement at $13.81/share for approximately $80 million gross proceeds from third-party investors.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $47.51, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Concentration risk — Pipeline: rosnilimab. Chart setup: RSI 47 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Analyst target $75.91 (+59.8%), stop $44.18 (−7.5%), A.R:R 5.8:1. Score 6.4/10, moderate confidence.
Analyst target: $75.91 (+59.8% upside). Analyst target $75.91 (+59.8%), stop $44.18 (−7.5%), A.R:R 5.8:1. Stop-loss: $44.18.
Concentration risk — Counterparty: GSK; Concentration risk — Pipeline: rosnilimab; Leverage penalty (D/E 25.5): -1.5.
AnaptysBio, Inc. trades at a P/E of N/A (forward 10.5). TrendMatrix value score: 5.9/10. Verdict: Hold.
15 analysts rate ANAB, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $87.
What does AnaptysBio, Inc. do?AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned...
AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned clinical-stage candidates: rosnilimab (Phase 2b completed for RA), ANB033 (Phase 1b for celiac disease and EoE), and ANB101 (Phase 1a). Revenue came from GSK milestones and royalties on Jemperli and Vanda licensing fees; in April 2026 those financial collaborations were spun off into First Tracks Biotherapeutics.